0      0

JL1115EH - JL1115EH: Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database

‐ Oct 23, 2023 4:00pm

Full author listing

Nilanjan Ghosh(1), Ruibin Wang,(2), Zhijie Ding (3), Xiaoxiao Lu (3), Jinghua He (2), Heena Mavani (2), Zaina P. Qureshi (3), Kerry A. Rogers (4)

1) Levine Cancer Institute, Atrium Health, Charlotte, NC, 2) Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3) Janssen Scientific Affairs, LLC, Horsham, PA, USA, 4) Division of Hematology, The Ohio State University, Columbus


You must be logged in and own this session in order to post comments.